Moderna (MRNA) Is Up 11.2% After Lowered 2025 Forecast and Pipeline Updates Is the Growth Story I...

Moderna (MRNA) Is Up 11.2% After Lowered 2025 Forecast and Pipeline Updates Is the Growth Story Intact?  simplywall.st

Moderna trims annual expenses outlook on lower production costs, R&D cuts - Reuters

Moderna trims annual expenses outlook on lower production costs, R&D cuts  Reuters

The Moderna, Inc. (NASDAQ:MRNA) Third-Quarter Results Are Out And Analysts Have Published New For...

The Moderna, Inc. (NASDAQ:MRNA) Third-Quarter Results Are Out And Analysts Have Published New Forecasts  Yahoo Finance

IR Insights: Recapping Our Third Quarter 2025 Earnings Report - Moderna

IR Insights: Recapping Our Third Quarter 2025 Earnings Report  Moderna

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Pri...

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint  The Register-Guard

Moderna (NASDAQ:MRNA) Price Target Cut to $21.00 by Analysts at Bank of America - MarketBeat

Moderna (NASDAQ:MRNA) Price Target Cut to $21.00 by Analysts at Bank of America  MarketBeat

Moderna’s Quarter Wasn’t As Bad as It Could Have Been. The Stock Is Up. - Barron's

Moderna’s Quarter Wasn’t As Bad as It Could Have Been. The Stock Is Up.  Barron's

Bernstein reiterates Market Perform rating on Moderna stock amid cost cuts - Investing.com

Bernstein reiterates Market Perform rating on Moderna stock amid cost cuts  Investing.com

Moderna's phase 3 norovirus study heads north again after struggling to find cases down south - F...

Moderna's phase 3 norovirus study heads north again after struggling to find cases down south  Fierce Biotech

Moderna leans on cost cuts, pipeline as vaccine sales dip - BioPharma Dive

Moderna leans on cost cuts, pipeline as vaccine sales dip  BioPharma Dive

Moderna Swings to a Loss on Fewer Covid-19 Vaccine Sales - WSJ - The Wall Street Journal

Moderna Swings to a Loss on Fewer Covid-19 Vaccine Sales - WSJ  The Wall Street Journal

Moderna's Cost-Cutting, Pipeline Catalysts Set Stage for 2026 Upside, UBS Says - MarketScreener

Moderna's Cost-Cutting, Pipeline Catalysts Set Stage for 2026 Upside, UBS Says  MarketScreener

Moderna Cuts Costs As Covid Vaccine Sales Decline; Shares Rise - Investor's Business Daily

Moderna Cuts Costs As Covid Vaccine Sales Decline; Shares Rise  Investor's Business Daily

Moderna says key study of its CMV vaccine, expected to be its next big win, failed - statnews.com

Moderna says key study of its CMV vaccine, expected to be its next big win, failed  statnews.com

Moderna eyes 2028 breakeven as Covid sales continue to drop - The Business Journals

Moderna eyes 2028 breakeven as Covid sales continue to drop  The Business Journals

Moderna (MRNA) Is Down 9.6% After Cutting 2025 Sales Outlook and Ending CMV Vaccine Program – Has...

Moderna (MRNA) Is Down 9.6% After Cutting 2025 Sales Outlook and Ending CMV Vaccine Program – Has Sentiment Shifted?  Yahoo Finance

Moderna halts development of birth defect vaccine after trial setback - Reuters

Moderna halts development of birth defect vaccine after trial setback  Reuters

How Recent Analyst Shifts Are Reshaping the Story for Moderna Investors - Yahoo Finance

How Recent Analyst Shifts Are Reshaping the Story for Moderna Investors  Yahoo Finance

Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic Cost Reductions Amid Revenue ... -...

Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic Cost Reductions Amid Revenue ...  Yahoo Finance

Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans - Yahoo Finance

Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans  Yahoo Finance

Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say - Nasdaq

Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say  Nasdaq

Moderna Gains on Sharp Cost Cuts as Covid Vaccine Declines - Bloomberg.com

Moderna Gains on Sharp Cost Cuts as Covid Vaccine Declines  Bloomberg.com

The Once and Future Moderna - statnews.com

The Once and Future Moderna  statnews.com

What Are Wall Street Analysts’ Target Price for Moderna Stock? - Barchart.com

What Are Wall Street Analysts’ Target Price for Moderna Stock?  Barchart.com

Moderna Posts Fourth-Straight Earnings Drop but the Bleeding Is Slowing - BioSpace

Moderna Posts Fourth-Straight Earnings Drop but the Bleeding Is Slowing  BioSpace

Despite a tough year, Moderna forges ahead with cancer therapies - statnews.com

Despite a tough year, Moderna forges ahead with cancer therapies  statnews.com

Moderna's losses narrow, Coach-maker's outlook disappoints - Yahoo Finance

Moderna's losses narrow, Coach-maker's outlook disappoints  Yahoo Finance

Moderna Posts Narrower Loss, Cost Cuts Boost Shares - Yahoo Finance

Moderna Posts Narrower Loss, Cost Cuts Boost Shares  Yahoo Finance

Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates  Yahoo Finance

Moderna: Q3 Earnings Snapshot - San Francisco Chronicle

Moderna: Q3 Earnings Snapshot  San Francisco Chronicle

Earnings call transcript: Moderna’s Q3 2025 earnings beat expectations - Investing.com

Earnings call transcript: Moderna’s Q3 2025 earnings beat expectations  Investing.com

Moderna faces CMV woes — but sees hope in cancer pipeline - statnews.com

Moderna faces CMV woes — but sees hope in cancer pipeline  statnews.com

Bernstein Reiterates Market Perform Rating on Moderna (MRNA) - StreetInsider

Bernstein Reiterates Market Perform Rating on Moderna (MRNA)  StreetInsider

Moderna says CMV vaccine once seen as future blockbuster fails key study - BioPharma Dive

Moderna says CMV vaccine once seen as future blockbuster fails key study  BioPharma Dive

No Signal for Myocarditis in Updated Moderna COVID Vax - Medscape

No Signal for Myocarditis in Updated Moderna COVID Vax  Medscape

Moderna scraps mRNA vaccine in congenital CMV on Phase III failure - Clinical Trials Arena

Moderna scraps mRNA vaccine in congenital CMV on Phase III failure  Clinical Trials Arena

Moderna eyes 2028 breakeven as COVID sales continue to drop - NBC Boston

Moderna eyes 2028 breakeven as COVID sales continue to drop  NBC Boston

Watch Moderna Posts Narrower Loss, Cost Cuts Boost Shares - Bloomberg.com

Watch Moderna Posts Narrower Loss, Cost Cuts Boost Shares  Bloomberg.com

Q3 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks - Markets Financial Content

Q3 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks  Markets Financial Content

Moderna co-founder Noubar Afeyan issues warning: Assault on science ‘isn’t going to stop at mRNA’...

Moderna co-founder Noubar Afeyan issues warning: Assault on science ‘isn’t going to stop at mRNA’  statnews.com

Should You Buy Moderna Stock Ahead of Q3 Earnings Report? - Yahoo Finance

Should You Buy Moderna Stock Ahead of Q3 Earnings Report?  Yahoo Finance

How Investors May Respond To Moderna (MRNA) Halting Development of mRNA-1647 CMV Vaccine - Yahoo ...

How Investors May Respond To Moderna (MRNA) Halting Development of mRNA-1647 CMV Vaccine  Yahoo Finance

Moderna Discontinues Development of Vaccine for Congenital CMV After Not Meeting Primary Efficacy...

Moderna Discontinues Development of Vaccine for Congenital CMV After Not Meeting Primary Efficacy Endpoint  Contagion Live

Moderna (NASDAQ:MRNA) Nasdaq Composite ETF Shapes MedTech Rise - Kalkine Media

Moderna (NASDAQ:MRNA) Nasdaq Composite ETF Shapes MedTech Rise  Kalkine Media

Moderna Q3 2025 Earnings Call Transcript - Benzinga

Moderna Q3 2025 Earnings Call Transcript  Benzinga

ESMO: Moderna's oncology efforts 'make sense' while government skeptical of vaccines - Fierce Bio...

ESMO: Moderna's oncology efforts 'make sense' while government skeptical of vaccines  Fierce Biotech

FY2027 EPS Estimate for Moderna Lowered by Analyst - MarketBeat

FY2027 EPS Estimate for Moderna Lowered by Analyst  MarketBeat

A bet on baldness - statnews.com

A bet on baldness  statnews.com

Moderna (MRNA) Outperforms Broader Market: What You Need to Know - Yahoo Finance

Moderna (MRNA) Outperforms Broader Market: What You Need to Know  Yahoo Finance

Moderna (NASDAQ:MRNA) Hits New 12-Month Low Following Analyst Downgrade - MarketBeat

Moderna (NASDAQ:MRNA) Hits New 12-Month Low Following Analyst Downgrade  MarketBeat

Moderna jumps after reporting much smaller Q3 loss than feared; sales also beat estimates - Sherw...

Moderna jumps after reporting much smaller Q3 loss than feared; sales also beat estimates  Sherwood News

Moderna sales down 45% but beat expectations - The Pharma Letter

Moderna sales down 45% but beat expectations  The Pharma Letter

Barclays Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00 - MarketBeat

Barclays Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00  MarketBeat

Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3 -...

Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3  Fierce Biotech

A Look at Moderna (MRNA) Valuation as Investors Weigh Post-Pandemic Growth Potential - Yahoo Finance

A Look at Moderna (MRNA) Valuation as Investors Weigh Post-Pandemic Growth Potential  Yahoo Finance

Moderna trims top end of full-year forecast on weak COVID vaccine sales - Yahoo! Finance Canada

Moderna trims top end of full-year forecast on weak COVID vaccine sales  Yahoo! Finance Canada

Moderna (MRNA) Dips More Than Broader Market: What You Should Know - Yahoo Finance

Moderna (MRNA) Dips More Than Broader Market: What You Should Know  Yahoo Finance

S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges - Investopedia

S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges  Investopedia

mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast - Benzinga

mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast  Benzinga

Analysts Are Neutral on Top Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), Moderna (MRNA) ...

Analysts Are Neutral on Top Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), Moderna (MRNA)  The Globe and Mail

Rothschild & Co Redburn Adjusts Price Target on Moderna to $36 From $53, Maintains Neutral Rating...

Rothschild & Co Redburn Adjusts Price Target on Moderna to $36 From $53, Maintains Neutral Rating  MarketScreener

Snap, Lyft, Moderna and Datadog rise premarket; Qualcomm falls - Investing.com

Snap, Lyft, Moderna and Datadog rise premarket; Qualcomm falls  Investing.com

Moderna Scraps CMV Vaccine After Phase III Fail - BioSpace

Moderna Scraps CMV Vaccine After Phase III Fail  BioSpace

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know  Yahoo Finance

Moderna posts Q3 beat even as weak vaccine sales drive revenue slump - MSN

Moderna posts Q3 beat even as weak vaccine sales drive revenue slump  MSN

Moderna Q3 preview: What to expect - Seeking Alpha

Moderna Q3 preview: What to expect  Seeking Alpha

Moderna says updated next-generation COVID shot shows strong immune response in patients - Reuters

Moderna says updated next-generation COVID shot shows strong immune response in patients  Reuters

Stocks making the biggest moves after hours: IBM, Tesla, Moderna and more - CNBC

Stocks making the biggest moves after hours: IBM, Tesla, Moderna and more  CNBC

Moderna - IBM

Moderna  IBM

Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust - Investor's Bus...

Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust  Investor's Business Daily

Moderna, Inc. (NASDAQ:MRNA) Q3 2025 Earnings Call Transcript - Insider Monkey

Moderna, Inc. (NASDAQ:MRNA) Q3 2025 Earnings Call Transcript  Insider Monkey

Moderna Drops Vaccine for Birth Defects After Trial Failure - Barron's

Moderna Drops Vaccine for Birth Defects After Trial Failure  Barron's

Why Moderna (MRNA) Shares Are Falling Today - Yahoo Finance

Why Moderna (MRNA) Shares Are Falling Today  Yahoo Finance

mRNA COVID vaccines may be helping some cancer patients fight tumors, researchers say - PBS

mRNA COVID vaccines may be helping some cancer patients fight tumors, researchers say  PBS

Moderna (MRNA): Assessing Valuation as Cancer Therapy Pipeline Expands with New Multiple Myeloma ...

Moderna (MRNA): Assessing Valuation as Cancer Therapy Pipeline Expands with New Multiple Myeloma Trial  Yahoo Finance

Another bump in Moderna’s neoantigen road | ApexOnco - Clinical Trials news and analysis - Oncolo...

Another bump in Moderna’s neoantigen road | ApexOnco - Clinical Trials news and analysis  Oncology Pipeline

Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Mu...

Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma  Tallahassee Democrat

Moderna Reports Q3 2025 Financial Results - The Globe and Mail

Moderna Reports Q3 2025 Financial Results  The Globe and Mail

IR Insights: Recapping Our Second Quarter 2025 Earnings Report - Moderna

IR Insights: Recapping Our Second Quarter 2025 Earnings Report  Moderna

Moderna cuts sales forecast on UK revenue delay, shares fall - Reuters

Moderna cuts sales forecast on UK revenue delay, shares fall  Reuters

Moderna Sharpens Its Focus On Cost Cuts And Partnerships - Finimize

Moderna Sharpens Its Focus On Cost Cuts And Partnerships  Finimize

Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow - CNBC

Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow  CNBC

Moderna’s Earnings Call: Balancing Achievements and Challenges - TipRanks

Moderna’s Earnings Call: Balancing Achievements and Challenges  TipRanks

Moderna (MRNA) Stock Trades Up, Here Is Why - Yahoo Finance

Moderna (MRNA) Stock Trades Up, Here Is Why  Yahoo Finance

Moderna gets full US approval for COVID shot in at-risk children 6 months and older - Reuters

Moderna gets full US approval for COVID shot in at-risk children 6 months and older  Reuters

Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - Yahoo Finance

Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025  Yahoo Finance

Moderna Named a Top Employer by Science for Eleventh Consecutive Year - Yahoo Finance

Moderna Named a Top Employer by Science for Eleventh Consecutive Year  Yahoo Finance

Moderna, Inc. $MRNA Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat

Moderna, Inc. $MRNA Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A.  MarketBeat

Moderna CEO Responds to RFK Jr.’s Crusade Against the Covid-19 Vaccine - WIRED

Moderna CEO Responds to RFK Jr.’s Crusade Against the Covid-19 Vaccine  WIRED

Moderna Q3 preview: What to expect - MSN

Moderna Q3 preview: What to expect  MSN

Moderna’s CMV vaccine fails Phase 3 study, ending long-shot prevention effort - Endpoints News

Moderna’s CMV vaccine fails Phase 3 study, ending long-shot prevention effort  Endpoints News

Moderna Cuts 2025 Forecast After Weak US Vaccine Sales - Finimize

Moderna Cuts 2025 Forecast After Weak US Vaccine Sales  Finimize

Moderna’s Cost-Cutting Efforts Offset by Revenue Challenges and Pipeline Uncertainties: Hold Rati...

Moderna’s Cost-Cutting Efforts Offset by Revenue Challenges and Pipeline Uncertainties: Hold Rating Maintained  TipRanks

New COVID vaccine says it’s for the ‘senior class’ — does it reduce side effects? - San Francisco...

New COVID vaccine says it’s for the ‘senior class’ — does it reduce side effects?  San Francisco Chronicle

Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics? - Yahoo F...

Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?  Yahoo Finance

US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults - Reuters

US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults  Reuters

UK Opens Moderna mRNA Vaccine Centre in Oxfordshire and Launches £50 Million Life-Sciences Fund -...

UK Opens Moderna mRNA Vaccine Centre in Oxfordshire and Launches £50 Million Life-Sciences Fund  Global Biodefense

Moderna Trims Revenue Forecast As Vaccine Demand Slips - Finimize

Moderna Trims Revenue Forecast As Vaccine Demand Slips  Finimize

Moderna seizes the omnichannel opportunity - The Trade Desk

Moderna seizes the omnichannel opportunity  The Trade Desk

How Renewed Scrutiny of Pediatric Vaccine Safety at Moderna (MRNA) Has Changed Its Investment Sto...

How Renewed Scrutiny of Pediatric Vaccine Safety at Moderna (MRNA) Has Changed Its Investment Story  Yahoo Finance